Allogene’s ALLO-329 Dual CAR T Shows Lupus Model Efficacy, Phase 1 Data June 2026
Allogene’s ALLO-329 dual CD19/CD70 allogeneic CAR T avoids immune rejection while achieving robust expansion, persistence and eliminating B and T cells in preclinical lupus models. Phase 1 RESOLUTION is enrolling patients at 20-million CAR T cell doses with reduced or no lymphodepletion; initial clinical data arrive June 2026.
1. Preclinical ALLO-329 Data
ALLO-329 integrates CD19 and CD70 CARs into an off-the-shelf allogeneic product that in lupus models eliminated both B and T cells, suppressed autoantibody production and demonstrated sustained CAR T cell expansion and persistence without host rejection.
2. Dagger® Technology and Anti-Rejection CAR
The proprietary Dagger® platform includes an optimized CD70 CAR designed to protect ALLO-329 cells from immune clearance, enabling robust proliferation of CD19-targeted CAR T cells in the absence of intensive lymphodepletion.
3. RESOLUTION Trial Design
The Phase 1 RESOLUTION trial is a 3+3 dose-escalation study enrolling systemic lupus erythematosus, scleroderma and inflammatory myositis cohorts at 20 million CAR T cell doses, with parallel arms receiving cyclophosphamide-only or no lymphodepletion.
4. Timeline, Fast Track Status and Market Potential
ALLO-329 holds three FDA Fast Track designations for lupus, myositis and scleroderma; initial translational and clinical readouts are expected in June 2026, with a further update by year-end, positioning the therapy for scalable autoimmune disease treatment.